ASLAN Pharmaceuticals Limited stock is down -37.59% since 30 days ago. The next earnings date is Mar 22, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a red month, as 16.67% of the previous 5 December’s closed higher than November. 100% of analysts rate it a buy.
ASLAN Pharmaceuticals Limited is a clinical-stage immunology focused biopharmaceutical company. The company's clinical portfolio comprises ASLAN004, a monoclonal therapy that is being developed in atopic dermatitis and other immunology indications. ASLAN003 is a small-molecule inhibitor of dihydroorotate dehydrogenase for the treatment of autoimmune conditions.